Price (delayed)
$24.29
Market cap
$4.05B
P/E Ratio
18.83
Dividend/share
N/A
EPS
$1.29
Enterprise value
$3.79B
Alkermes plc is a biopharmaceutical company that focuses on central nervous system diseases such as such as schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 by
There are no recent dividends present for ALKS.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.